- Home
- CODI vs ALT Comparison
CODI vs ALT Comparison
Compare CODI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODI | ALT |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.8M | 415.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CODI | ALT |
|---|---|---|
| Price | $6.72 | $3.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $8.00 | ★ $17.67 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $1.14 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $4.58 | $2.91 |
| 52 Week High | $18.84 | $7.73 |
Technical Indicators
Market Signals| Indicator | CODI | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 30.09 |
| Support Level | $6.15 | $2.91 |
| Resistance Level | $7.04 | $4.25 |
| Average True Range (ATR) | 0.37 | 0.18 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 85.01 | 2.94 |
Price Performance
Historical ComparisonAbout CODI D/B/A Compass Diversified Holdings Shares of Beneficial Interest
Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.